 SAN DIEGO, Oct. 06, 2022 GLOBE NEWSWIRE -- Capricor Therapeutics NASDAQ: CAPR a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Company will present one-year safety and efficacy results from its HOPE-2 open-label extension study with lead asset CAP-1002 for treating Duchenne muscular dystrophy DMD. These data will be featured in a poster presentation at this years World Muscle Society Congress WMS being held both virtually and in Halifax, Nova Scotia, Canada from October 11-15, 2022. 